Bioglutide (NA-931) Dosage Guide: What Phase 2 Data Shows

What Is Bioglutide (NA-931)?#

Bioglutide (NA-931) is a first-in-class, orally active small-molecule quadruple receptor agonist developed by Biomed Industries. Unlike existing GLP-1 drugs that target one or two receptors, bioglutide simultaneously activates four metabolic hormone receptors: IGF-1, GLP-1, GIP, and glucagon. It is derived from a cyclic IGF-1 fragment and designed as a once-daily oral capsule.

The drug's four-receptor mechanism is designed to address limitations of current GLP-1 agonists, particularly muscle mass loss during weight reduction (the IGF-1 component) and the high rate of gastrointestinal side effects (the balanced multi-receptor approach).

As of March 2026, bioglutide has completed Phase 1 and Phase 2 clinical trials and is not approved for any indication. Phase 3 trials are planned.

Phase 1 Dose Escalation Data#

The Phase 1 study (NCT06615700) enrolled 74 otherwise healthy overweight and obese adults and tested multiple ascending doses up to 150 mg daily over 28 days.

Key findings from Phase 1:

• Doses of 60 mg and above showed sustained weight loss effects
• The highest dose group achieved 6.4% mean weight loss at Day 28
• Weight loss was maintained or continued to improve at Day 35, seven days after the last dose, suggesting a sustained pharmacological effect
• The drug was administered as a once-daily oral capsule

Phase 2 Dosing and Results#

The Phase 2 study (NCT06564753) enrolled 125 adults with obesity (BMI 30 or greater) or overweight with comorbidities and tested ascending doses up to 150 mg daily over 13 weeks.

Results at the 150 mg daily dose:

• 13.8% mean body weight reduction at 13 weeks (12.4% placebo-adjusted)
• 72% of participants achieved at least 12% weight loss
• Gastrointestinal side effects were minimal: 83% reported insignificant GI effects, 7.3% experienced mild nausea, and 6.3% experienced diarrhea
• No fasting or food restrictions were required for dosing
• Blood levels were consistent regardless of fasting state or consumption of a high-fat meal

The exact titration schedule (how doses were escalated from lower to higher amounts) has not been publicly disclosed in detail. Conference abstracts describe "ascending doses up to 150 mg daily" without specifying the step-by-step escalation protocol.

For complete dosing protocol details, see the bioglutide dosing page.

Combination Therapy Trial#

A Phase 2 combination study (NCT06732245) is enrolling 224 participants to test bioglutide 150 mg daily combined with tirzepatide subcutaneous injection. Preclinical studies showed synergistic effects on weight, glucose, and lipids. This trial is designed to assess whether the combination produces greater weight loss while reducing GI adverse events and preserving muscle mass compared to either drug alone.

How Bioglutide Dosing Compares to Other GLP-1 Agonists#

The most notable differences are the oral route of administration, the shorter trial duration showing substantial weight loss, and the markedly lower rate of GI side effects. However, direct head-to-head comparisons have not been conducted, and the Phase 2 trial was only 13 weeks long compared to the much longer pivotal trials for semaglutide and tirzepatide.

Important Caveats#

Bioglutide is an investigational drug that is not FDA-approved for any indication. The dosing information in this article is drawn from clinical trial data and conference abstracts, not prescribing information.

Key limitations of current data:

• Small sample sizes: Phase 1 (n=74) and Phase 2 (n=125) trials
• Short duration: Maximum 13 weeks of treatment data
• No peer-reviewed publications: Phase 2 results are available only as conference abstracts as of early 2026
• Unknown long-term safety: No data beyond 13 weeks of continuous use
• No head-to-head trials: Comparisons to semaglutide and tirzepatide are indirect

Frequently Asked Questions#